February 2026
1. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
   Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
   Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
   

   >> Share

   
   January 2026
2. YURGELONIS I, Rai DK, Li Z, Washington B, et al
   Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
   Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
   

   >> Share

   
   September 2025
3. ALVAREZ-RIBELLES A, Fernandez-Rodriguez S, Carrasco-Hernandez I, Blas-Garcia A, et al
   Differential Effects of Antiretroviral HIV Integrase Inhibitors on Vascular Cell Adhesion Molecules.
   Antiviral Res. 2025 Sep 11:106283. doi: 10.1016/j.antiviral.2025.106283.
   

   >> Share

   
   March 2025
4. DULION B, Olali AZ, Patel N, Virdi AK, et al
   Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate.
   Antiviral Res. 2025;237:106151.
   

   >> Share

   
   
5. WEISS S, Alvarez RA, Goff M, Li H, et al
   High HIV-1 viremia and low anti-Env antibody responses are associated with delayed treatment response to fostemsavir in highly treatment-experienced individuals.
   Antiviral Res. 2025;235:106096.
   

   >> Share

   
   December 2024
6. HERSHKOVICH L, Cotler SJ, Shekhtman L, Bazinet M, et al
   HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.
   Antiviral Res. 2024 Dec 18:106061. doi: 10.1016/j.antiviral.2024.106061.
   

   >> Share

   
   October 2024
7. GARCIA-MARTINEZ P, Gisbert-Ferrandiz L, Alvarez A, Esplugues JV, et al
   Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction.
   Antiviral Res. 2024;231:106020.
   

   >> Share

   
   September 2024
8. JOSEPH DAVEY D, Dadan S, Bheemraj K, Waitt C, et al
   Evaluation of Pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in Pregnant and Postpartum Women in South Africa: PrEP-PP PK Study.
   Antiviral Res. 2024 Sep 25:106014. doi: 10.1016/j.antiviral.2024.106014.
   

   >> Share

   
   August 2024
9. TAO K, Zhou J, Nagarajan P, Tzou PL, et al
   Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.
   Antiviral Res. 2024;230:105988.
   

   >> Share

   
   July 2024
10. RAUCH S, Costacurta F, Schoppe H, Peng JY, et al
    Highly specific SARS-CoV-2 main protease (M(pro)) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.
    Antiviral Res. 2024 Jul 23:105969. doi: 10.1016/j.antiviral.2024.105969.
    

    >> Share

    
    April 2024
11. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
    SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
    

    >> Share

    
    March 2024
12. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    

    >> Share

    
    
13. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    

    >> Share

    
    December 2023
14. ZUR M, Peselev T, Yanko S, Rotshild V, et al
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    

    >> Share

    
    November 2023
15. GALLUCCI L, Bazire J, Davidson AD, Shytaj IL, et al
    Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro.
    Antiviral Res. 2023;221:105766.
    

    >> Share

    
    June 2023
16. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    

    >> Share

    
    February 2023
17. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    

    >> Share

    
    November 2022
18. CHEN X, Ding W, Cui X, Wei J, et al
    HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway.
    Antiviral Res. 2022;208:105463.
    

    >> Share

    
    May 2022
19. LIU T, Sun Q, Gu J, Cen S, et al
    Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D.
    Antiviral Res. 2022;203:105348.
    

    >> Share

    
    April 2022
20. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
    HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Antiviral Res. 2022;202:105311.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share